Development of a clinical model to predict secondary non-response of infliximab treatment in Crohn ’s disease

ConclusionsThe study presents a model to predict non-response to IFX in CD, which incorporates previous surgery, ESR, CRP, and TNFRSF1B (676 T>G). This model can be used to help clinicians adjust the therapeutic strategy and CD patients avoid unnecessary exposure to IFX.
Source: International Journal of Colorectal Disease - Category: Gastroenterology Source Type: research